Tobramycin indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Tobramycin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATI...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Indications and Usage== | |||
TOBI® is indicated for the management of [[cystic fibrosis]] patients with [[P. aeruginosa]]. | |||
Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >75% predicted, or patients colonized with Burkholderia cepacia (see CLINICAL STUDIES).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f9e516-6bf6-4e30-8dde-8833c25c2560 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f9e516-6bf6-4e30-8dde-8833c25c2560 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 20:05, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
TOBI® is indicated for the management of cystic fibrosis patients with P. aeruginosa.
Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >75% predicted, or patients colonized with Burkholderia cepacia (see CLINICAL STUDIES).[1]
References
Adapted from the FDA Package Insert.